LB946 Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment

In 2 monotherapy phase 3 studies (ECZTRA 1 and 2) of patients with moderate-to-severe atopic dermatitis (AD) treated tralokinumab, one the primary endpoints was IGA 0/1 (clear/almost clear) at Week 16. However, in a heterogeneous disease like AD, other important clinically meaningful parameters include improvement signs, symptoms, and/or quality life. We assessed impact tralokinumab on AD life IGA>1 Partial responders, defined as 16, were included post-hoc analysis ECZTRA 2. Non-responder imputation (NRI) used for who utilized rescue medication or had missing data, observed to address data (AO). Clinically changes EASI-50, ≥3-point Worst Daily Pruritus NRS (itch), ≥4-point DLQI. At 960 358 placebo by NRI (AO: n=898, n=327). 49% (NRI), 82% (AO) arm achieved EASI, itch, 33% met 23% Itch NRS, 41% DLQI 55%, 40%, 71%). significantly (P<0.001) greater responses across all versus placebo. 16 weeks treatment partial responders